Grifols SA (GRFS)
7.415
+0.06
(+0.88%)
USD |
NASDAQ |
Sep 28, 16:00
7.415
0.00 (0.00%)
After-Hours: 17:28
Grifols Research and Development Expense (TTM) : 477.82M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 477.82M |
| March 31, 2026 | 471.52M |
| December 31, 2025 | 467.31M |
| September 30, 2025 | 430.83M |
| June 30, 2025 | 413.98M |
| March 31, 2025 | 394.23M |
| December 31, 2024 | 391.33M |
| September 30, 2024 | 390.78M |
| June 30, 2024 | 390.46M |
| March 31, 2024 | 402.14M |
| December 31, 2023 | 412.20M |
| September 30, 2023 | 376.57M |
| June 30, 2023 | 376.62M |
| March 31, 2023 | 374.41M |
| March 31, 2021 | 347.93M |
| December 31, 2020 | 336.20M |
| September 30, 2020 | 323.00M |
| June 30, 2020 | 315.67M |
| March 31, 2020 | 312.51M |
| December 31, 2019 | 308.84M |
| September 30, 2019 | 305.85M |
| June 30, 2019 | 297.52M |
| March 31, 2019 | 282.38M |
| December 31, 2018 | 277.62M |
| Date | Value |
|---|---|
| September 30, 2018 | 322.85M |
| June 30, 2018 | 325.96M |
| March 31, 2018 | 327.25M |
| December 31, 2017 | 323.99M |
| September 30, 2017 | 246.90M |
| June 30, 2017 | 230.84M |
| March 31, 2017 | 218.54M |
| December 31, 2016 | 204.28M |
| September 30, 2016 | 224.81M |
| June 30, 2016 | 226.41M |
| March 31, 2016 | 228.70M |
| December 31, 2015 | 233.29M |
| September 30, 2015 | 231.01M |
| June 30, 2015 | 230.72M |
| March 31, 2015 | 236.37M |
| December 31, 2014 | 234.90M |
| September 30, 2014 | 210.22M |
| June 30, 2014 | 191.85M |
| March 31, 2014 | 169.52M |
| December 31, 2013 | 156.29M |
| September 30, 2013 | 158.69M |
| June 30, 2013 | 160.55M |
| March 31, 2013 | 161.40M |
| December 31, 2012 | 159.85M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Evaxion AS | 10.27M |
| argenx SE | 1.640B |
| Autolus Therapeutics Plc | 112.42M |
| Akari Therapeutics Plc | 4.869M |
| Pharma Mar SA | 110.74M |